Genetic therapeutic approaches for Duchenne muscular dystrophy

Area of Science:

• Genetics
• Molecular Biology
• Biotechnology

Background:

• Duchenne muscular dystrophy (DMD) remains incurable despite extensive research following the DMD gene discovery.
• Current research explores cell-based therapies and pharmacological approaches to upregulate dystrophin or utrophin.
• Genetic-based strategies are emerging as promising avenues for ameliorating the DMD phenotype.

Purpose of the Study:

• To review recent advances in genetic-based therapeutic strategies for Duchenne muscular dystrophy.
• To discuss the challenges and hurdles in developing effective and comprehensive DMD treatments.
• To evaluate approaches including gene reintroduction, exon skipping, and genome editing.

Main Methods:

• Review of genetic therapeutic strategies for DMD.
• Analysis of viral vector-mediated gene reintroduction.
• Examination of antisense oligonucleotide-induced exon skipping for transcript correction.
• Discussion of genome editing for direct DMD gene modification.

Main Results:

• Significant progress has been made in gene therapy, exon skipping, and genome editing for DMD.
• These genetic approaches aim to restore the open reading frame or introduce a functional DMD gene copy.
• Challenges include achieving systemic delivery to all musculature and ensuring long-term efficacy.

Conclusions:

• Genetic therapies show considerable promise for treating Duchenne muscular dystrophy.
• Overcoming hurdles such as systemic targeting, long-term effects, and immune responses is crucial for clinical success.
• Further research is needed to translate these advances into effective, safe, and comprehensive treatments for all patients.